Axonics Modulation Technologies Stock Forecast, Price & News

Axonics Modulation Technologies' stock was trading at $30.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AXNX shares have increased by 66.5% and is now trading at $50.32.
View which stocks have been most impacted by COVID-19.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics Modulation Technologies in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Axonics Modulation Technologies.

Axonics Modulation Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Axonics Modulation Technologies.

Axonics Modulation Technologies will be holding an earnings conference call on Wednesday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.54) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.11. The company had revenue of $15.21 million for the quarter, compared to analyst estimates of $5.06 million. Axonics Modulation Technologies had a negative return on equity of 44.13% and a negative net margin of 155.91%. Axonics Modulation Technologies's revenue for the quarter was up 922.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.68) EPS.
View Axonics Modulation Technologies' earnings history.

9 Wall Street analysts have issued 12-month target prices for Axonics Modulation Technologies' shares. Their forecasts range from $39.00 to $77.00. On average, they anticipate Axonics Modulation Technologies' share price to reach $52.56 in the next year. This suggests a possible upside of 4.4% from the stock's current price.
View analysts' price targets for Axonics Modulation Technologies.

Some companies that are related to Axonics Modulation Technologies include Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Hill-Rom (HRC), Haemonetics (HAE), Nevro (NVRO), Globus Medical (GMED), ICU Medical (ICUI), Integra LifeSciences (IART), Inspire Medical Systems (INSP), Inari Medical (NARI), Merit Medical Systems (MMSI), Glaukos (GKOS), NuVasive (NUVA), ShockWave Medical (SWAV) and Silk Road Medical (SILK).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics Modulation Technologies investors own include Raytheon Technologies (RTX), Honeywell International (HON), Oasis Petroleum (OAS), Pfizer (PFE), The Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

(AXNX) raised $100 million in an IPO on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Axonics Modulation Technologies trades on the NASDAQ under the ticker symbol "AXNX."

Axonics Modulation Technologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (1.32%), Rhenman & Partners Asset Management AB (1.16%), Columbus Circle Investors (0.35%), Nachman Norwood & Parrott Inc (0.00%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Axonics Modulation Technologies stock include Alfred J Ford, Jr, Andera Partners, Bakker Juliet Tammenoms, Cormorant Asset Management, Lp, Danny L Dearen, Geoff Pardo, Healthcare Holding BV Gilde, John Woock, Michael V Williamson, Nancy Lynn Md Snyderman, Raphael Wisniewski, Raymond W Cohen and Rinda Sama.
View institutional ownership trends for Axonics Modulation Technologies.

AXNX stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, and Rhenman & Partners Asset Management AB. Company insiders that have sold Axonics Modulation Technologies company stock in the last year include Alfred J Ford, Jr, Andera Partners, Bakker Juliet Tammenoms, Danny L Dearen, John Woock, Raphael Wisniewski, Raymond W Cohen, and Rinda Sama.
View insider buying and selling activity for Axonics Modulation Technologies.

AXNX stock was purchased by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Nachman Norwood & Parrott Inc, and Nisa Investment Advisors LLC. Company insiders that have bought Axonics Modulation Technologies stock in the last two years include Bakker Juliet Tammenoms, Cormorant Asset Management, Lp, Healthcare Holding BV Gilde, Nancy Lynn Md Snyderman, and Raymond W Cohen.
View insider buying and selling activity for Axonics Modulation Technologies.

Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AXNX stock can currently be purchased for approximately $50.32.

Axonics Modulation Technologies has a market capitalization of $1.99 billion and generates $13.82 million in revenue each year. The company earns $-79,930,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis. Axonics Modulation Technologies employs 302 workers across the globe.

The official website for Axonics Modulation Technologies is www.axonics.com.

Axonics Modulation Technologies' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company can be reached via phone at 949-396-6322.